Clearpoint Neuro Stock EBITDA

CLPT Stock

USD 15.33 1.07 6.52%

Clearpoint Neuro fundamentals help investors to digest information that contributes to Clearpoint Neuro's financial success or failures. It also enables traders to predict the movement of Clearpoint Stock. The fundamental analysis module provides a way to measure Clearpoint Neuro's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clearpoint Neuro stock.

		Last Reported	Projected for Next Year
	EBITDA	-21 M	-19.9 M

EBITDA is likely to gain to about (19.9 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Clearpoint Neuro Company EBITDA Analysis

Clearpoint Neuro's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Clearpoint Neuro EBITDA

(20.99 M)

Most of Clearpoint Neuro's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clearpoint Neuro is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Clearpoint EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Clearpoint Neuro is extremely important. It helps to project a fair market value of Clearpoint Stock properly, considering its historical fundamentals such as EBITDA. Since Clearpoint Neuro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Clearpoint Neuro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Clearpoint Neuro's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Retained Earnings	Intangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock	Deferred Long Term Liab
Total Assets		0.92	0.07	-0.87	-0.59	0.69	0.28	1.0	-0.43	-0.14	0.42	-0.01	0.61	0.62	0.9	0.76	0.86	0.96	-0.19	0.97	0.91	0.69
Total Stockholder Equity	0.92		-0.04	-0.92	-0.74	0.74	-0.06	0.93	-0.53	-0.12	0.59	-0.16	0.42	0.43	0.85	0.61	0.88	0.88	-0.32	0.89	0.86	0.64
Current Deferred Revenue	0.07	-0.04		0.01	0.3	0.43	0.58	0.05	0.0	-0.36	-0.46	0.77	0.08	0.1	0.31	0.08	0.4	0.17	-0.6	0.17	0.38	0.48
Net Debt	-0.87	-0.92	0.01		0.51	-0.54	0.03	-0.89	0.38	0.14	-0.41	0.19	-0.27	-0.27	-0.74	-0.58	-0.83	-0.87	0.17	-0.88	-0.75	-0.45
Accounts Payable	-0.59	-0.74	0.3	0.51		-0.67	0.3	-0.59	0.68	0.07	-0.78	0.42	-0.46	-0.46	-0.61	-0.49	-0.53	-0.46	0.3	-0.48	-0.58	-0.43
Net Receivables	0.69	0.74	0.43	-0.54	-0.67		0.23	0.67	-0.47	-0.17	0.46	0.17	0.54	0.56	0.84	0.55	0.88	0.68	-0.79	0.68	0.88	0.84
Total Liab	0.28	-0.06	0.58	0.03	0.3	0.23		0.26	0.22	-0.1	-0.37	0.51	0.61	0.62	0.24	0.51	0.21	0.37	-0.14	0.35	0.34	0.3
Total Current Assets	1.0	0.93	0.05	-0.89	-0.59	0.67	0.26		-0.43	-0.14	0.43	-0.04	0.58	0.59	0.89	0.75	0.85	0.97	-0.17	0.97	0.9	0.66
Short Term Debt	-0.43	-0.53	0.0	0.38	0.68	-0.47	0.22	-0.43		0.63	-0.35	0.12	-0.42	-0.42	-0.56	-0.47	-0.4	-0.32	0.17	-0.36	-0.5	-0.32
Common Stock	-0.14	-0.12	-0.36	0.14	0.07	-0.17	-0.1	-0.14	0.63		0.08	-0.14	-0.2	-0.2	-0.3	-0.21	-0.2	-0.14	0.08	-0.16	-0.23	-0.13
Retained Earnings	0.42	0.59	-0.46	-0.41	-0.78	0.46	-0.37	0.43	-0.35	0.08		-0.72	0.27	0.27	0.41	0.3	0.34	0.27	-0.18	0.29	0.37	0.26
Intangible Assets	-0.01	-0.16	0.77	0.19	0.42	0.17	0.51	-0.04	0.12	-0.14	-0.72		-0.02	0.0	0.16	-0.14	0.19	0.1	-0.29	0.08	0.2	0.45
Long Term Debt	0.61	0.42	0.08	-0.27	-0.46	0.54	0.61	0.58	-0.42	-0.2	0.27	-0.02		1.0	0.52	0.89	0.4	0.58	-0.19	0.58	0.6	0.36
Long Term Debt Total	0.62	0.43	0.1	-0.27	-0.46	0.56	0.62	0.59	-0.42	-0.2	0.27	0.0	1.0		0.55	0.89	0.42	0.58	-0.2	0.58	0.62	0.4
Capital Surpluse	0.9	0.85	0.31	-0.74	-0.61	0.84	0.24	0.89	-0.56	-0.3	0.41	0.16	0.52	0.55		0.62	0.9	0.83	-0.4	0.84	0.95	0.88
Property Plant Equipment	0.76	0.61	0.08	-0.58	-0.49	0.55	0.51	0.75	-0.47	-0.21	0.3	-0.14	0.89	0.89	0.62		0.57	0.74	-0.17	0.76	0.71	0.32
Net Tangible Assets	0.86	0.88	0.4	-0.83	-0.53	0.88	0.21	0.85	-0.4	-0.2	0.34	0.19	0.4	0.42	0.9	0.57		0.88	-0.61	0.88	0.94	0.81
Net Invested Capital	0.96	0.88	0.17	-0.87	-0.46	0.68	0.37	0.97	-0.32	-0.14	0.27	0.1	0.58	0.58	0.83	0.74	0.88		-0.25	1.0	0.89	0.64
Short Long Term Debt	-0.19	-0.32	-0.6	0.17	0.3	-0.79	-0.14	-0.17	0.17	0.08	-0.18	-0.29	-0.19	-0.2	-0.4	-0.17	-0.61	-0.25		-0.25	-0.5	-0.56
Net Working Capital	0.97	0.89	0.17	-0.88	-0.48	0.68	0.35	0.97	-0.36	-0.16	0.29	0.08	0.58	0.58	0.84	0.76	0.88	1.0	-0.25		0.9	0.64
Capital Stock	0.91	0.86	0.38	-0.75	-0.58	0.88	0.34	0.9	-0.5	-0.23	0.37	0.2	0.6	0.62	0.95	0.71	0.94	0.89	-0.5	0.9		0.85
Deferred Long Term Liab	0.69	0.64	0.48	-0.45	-0.43	0.84	0.3	0.66	-0.32	-0.13	0.26	0.45	0.36	0.4	0.88	0.32	0.81	0.64	-0.56	0.64	0.85

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Clearpoint Neuro

Ebitda Over Time

Clearpoint Ebitda

Ebitda

(19.94 Million)

At this time, Clearpoint Neuro's EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Clearpoint Neuro reported earnings before interest,tax, depreciation and amortization of (20.99 Million). This is 102.39% lower than that of the Health Care Equipment & Supplies sector and 103.27% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.54% higher than that of the company.

Clearpoint EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clearpoint Neuro's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics of similar companies.

Clearpoint Neuro is currently under evaluation in ebitda category among its peers.

Clearpoint Neuro Current Valuation Drivers

We derive many important indicators used in calculating different scores of Clearpoint Neuro from analyzing Clearpoint Neuro's financial statements. These drivers represent accounts that assess Clearpoint Neuro's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Clearpoint Neuro's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	63.1M	251.9M	232.6M	204.8M	167.1M	83.6M
Enterprise Value	59.9M	256.0M	190.8M	189.2M	157.9M	165.8M

Clearpoint Neuro ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Clearpoint Neuro's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Clearpoint Neuro's managers, analysts, and investors.

Environmental

Governance

Social

Clearpoint Neuro Institutional Holders

Institutional Holdings refers to the ownership stake in Clearpoint Neuro that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Clearpoint Neuro's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Clearpoint Neuro's value.

		Shares
Legato Capital Management Llc	2024-09-30	159 K
Lane Generational Llc	2024-09-30	157.7 K
Susquehanna International Group, Llp	2024-09-30	151 K
Jane Street Group Llc	2024-06-30	144.1 K
Parsons Capital Management Inc	2024-09-30	139 K
Qube Research & Technologies	2024-09-30	124.5 K
State Street Corp	2024-09-30	105.2 K
Citigroup Inc	2024-09-30	90.6 K
Citadel Advisors Llc	2024-09-30	85.9 K
Vanguard Group Inc	2024-09-30	1.2 M
Essex Investment Management Company, Llc	2024-09-30	463.9 K

Clearpoint Fundamentals

	Return On Equity	-0.68
	Return On Asset	-0.28
	Profit Margin	(0.60) %
	Operating Margin	(0.64) %
	Current Valuation	404.86 M
	Shares Outstanding	27.58 M
	Shares Owned By Insiders	7.83 %
	Shares Owned By Institutions	30.40 %
	Number Of Shares Shorted	736.23 K
	Price To Earning	(3.36) X
	Price To Book	14.58 X
	Price To Sales	13.89 X
	Revenue	23.95 M
	Gross Profit	13.53 M
	EBITDA	(20.99 M)
	Net Income	(22.09 M)
	Cash And Equivalents	45.14 M
	Cash Per Share	1.84 X
	Total Debt	13.94 M
	Debt To Equity	0.28 %
	Current Ratio	10.33 X
	Book Value Per Share	1.05 X
	Cash Flow From Operations	(13.72 M)
	Short Ratio	3.19 X
	Earnings Per Share	(0.69) X
	Price To Earnings To Growth	(0.46) X
	Target Price	17.0
	Number Of Employees	107
	Beta	1.11
	Market Capitalization	422.74 M
	Total Asset	42.66 M
	Retained Earnings	(172.46 M)
	Working Capital	28.74 M
	Current Asset	8.1 M
	Current Liabilities	1.85 M
	Net Asset	42.66 M

About Clearpoint Neuro Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Clearpoint Stock Analysis

When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC